Physician profile
Warren Lee
NPI 1487661955
$11,312.43
in general payments reported to CMS, 2019-2025
26 companies · $3,322 in 2025
The $3,322 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $983 · 2022: $1,971 · 2023: $2,281 · 2024: $2,755 · 2025: $3,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,837 · Education: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,837.20 |
| Education | $520.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,456.48 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $1,208.39 | 2021-2025 | |
| Janssen Biotech, INC. | $963.71 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $774.28 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $585.69 | 2023-2024 | Vtama |
| Pfizer INC. | $564.75 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $544.72 | 2021-2025 | Dupixent |
| Genzyme Corporation | $511.67 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $429.86 | 2022-2025 | Sotyktu |
| Organon LLC | $408.11 | 2025 | Vtama |
| Ucb, INC. | $361.89 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $335.97 | 2022-2025 | Siliq, Cabtreo, Arazlo |
| Arcutis Biotherapeutics, INC. | $326.34 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $320.25 | 2022-2025 | |
| Incyte Corporation | $319.44 | 2022-2025 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $221.58 | 2021-2025 | Otezla, Otezla, Amjevita |
| Galderma Laboratories, L.P. | $215.20 | 2021-2025 | Aklief, Oracea, Epsolay |
| Leo Pharma INC. | $184.40 | 2023-2025 | Adbry |
| Almirall LLC | $170.74 | 2022-2023 | Seysara |
| Sun Pharmaceutical Industries INC. | $160.70 | 2021-2025 | Odomzo, Blu-U |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Journey Medical Corporation | $47.90 | 2022-2025 | |
| Genentech USA, INC. | $32.97 | 2022-2023 | Erivedge |
| Sandoz INC. | $32.18 | 2023-2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.16 | 2023 | Spevigo |
| Botanix Sb INC | $27.06 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.